F

resh off a big clinical trial victory in postpartum depression, Sage Therapeutics (SAGE) announced yet more good news Thursday: Positive results from a mid-stage clinical trial for a pill to treat people with major depressive disorder. The drug appears to work quickly, though its effects diminish over time.

If Thursday’s results are confirmed in later phase 3 clinical trials, the Sage pill, known as SAGE-217, could become one of the first medicines in years with a new mechanism of action to be approved for the treatment of depression.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Biotech newsletter — The Readout

Your daily guide to what’s new in biotech.